Santhera Pharmaceuticals (Switzerland) Performance
| SANN Stock | CHF 14.90 0.10 0.67% |
Santhera Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The entity has a beta of 0.0563, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Santhera Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Santhera Pharmaceuticals is expected to be smaller as well. Santhera Pharmaceuticals right now has a risk of 3.54%. Please validate Santhera Pharmaceuticals treynor ratio, value at risk, and the relationship between the sortino ratio and maximum drawdown , to decide if Santhera Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Santhera Pharmaceuticals Holding are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Santhera Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 12.4 M | |
| Total Cashflows From Investing Activities | 69 K |
Santhera |
Santhera Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,382 in Santhera Pharmaceuticals Holding on December 29, 2024 and sell it today you would earn a total of 108.00 from holding Santhera Pharmaceuticals Holding or generate 7.81% return on investment over 90 days. Santhera Pharmaceuticals Holding is generating 0.1823% of daily returns and assumes 3.5383% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Santhera, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Santhera Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Santhera Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Santhera Pharmaceuticals Holding, and traders can use it to determine the average amount a Santhera Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0515
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SANN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.54 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Santhera Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Santhera Pharmaceuticals by adding it to a well-diversified portfolio.
Santhera Pharmaceuticals Fundamentals Growth
Santhera Stock prices reflect investors' perceptions of the future prospects and financial health of Santhera Pharmaceuticals, and Santhera Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Santhera Stock performance.
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 58.16 M | |||
| Shares Outstanding | 61.81 M | |||
| Price To Earning | (7.01) X | |||
| Price To Book | 30.52 X | |||
| Price To Sales | 276.19 X | |||
| Revenue | (1.59 M) | |||
| EBITDA | (34.57 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 2.07 X | |||
| Total Debt | 27 M | |||
| Debt To Equity | 196.00 % | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.62) X | |||
| Total Asset | 91.12 M | |||
About Santhera Pharmaceuticals Performance
Evaluating Santhera Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Santhera Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Santhera Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people.Things to note about Santhera Pharmaceuticals performance evaluation
Checking the ongoing alerts about Santhera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Santhera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Santhera Pharmaceuticals had very high historical volatility over the last 90 days | |
| Santhera Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Santhera Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Santhera Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Santhera Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Santhera Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Santhera Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Santhera Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Santhera Pharmaceuticals' stock. These opinions can provide insight into Santhera Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.